INS and Obesity: In conclusion, the proteasome inhibitor PS-341 alleviates chronic low-grade inflammation while improving insulin sensitivity through upregulation of TM4 expression and may be a candidate for the treatment of metabolic inflammatory diseases, such as obesity and type 2 diabetes.